期刊文献+

老年卡氏肺孢子菌肺炎的诊断和治疗 被引量:8

Diagnosis and Treatment of Pneumocystis Carinii Pneumonia in aged Patients
下载PDF
导出
摘要 目的提高对老年人群患卡氏肺孢子菌肺炎(PCP)的诊治和认识。方法对二例老年PCP患者的诊断和治疗经过进行总结和讨论。结果二例老年PCP患者经临床体格检查、影像学检查和痰标本涂片姬姆萨(或甲紫色蓝)染色查到卡氏肺孢子菌(PC)或PCR(+)而获诊。一例PCP患者选用复方磺胺甲口恶唑(SMZco)治愈,另一例初用SMZco后因为发生不良反应而改用卡泊芬净治愈。结论PCP是在老年肺癌或长期住院机械通气患者易患的机会性感染,通过痰标本PCR检测阳性或痰涂片染色查到PC而确诊,应与其他肺炎做鉴别诊断。PCP治疗首选SMZco,当SMZco发生不良反应或者失败时可改用卡泊芬净治疗。 Objective To deepen our understanding of diagnoses and treatment of pneumocystis carinii pneumonia (PCP) in aged patients. Methods We reviewed the diagnosis and treatment of two aged patients with PCP. Results The two aged patients were given final diagnosis when pneumocystis carinii (PC) or PCR ( + ) was discovered by clinical features, radiographic abnormalities and sputum specimen smear Giemsa stain (or grocott). One case was treated with SMZco, the other with caspofungin due to side reaction of SMZco. Conclusion PCP is a kind of opportunistic infection which has vulnerability for aged patients with lung cancer and MV patients with long - term hospitalization. It can be given a final diagnosis by positive PCR in sputum specimen or PC discovered in sputum smear staining. Differential diagnosis should be done between PCP and other kinds of pneumonia. SMZco is the first choice in the treatment of PCP, but caspofungin can be used when SMZco fails or produces side reaction.
出处 《中国全科医学》 CAS CSCD 2008年第4期279-281,共3页 Chinese General Practice
关键词 肺炎 肺囊虫性菌 老年人 Pneumonia, pneumocystis carinii Elderly
  • 相关文献

参考文献8

二级参考文献50

  • 1瞿介明,何礼贤,李锡莹,胡必杰,蒋金根,张元芳.肾移植术后并发卡氏肺孢子虫肺炎[J].中华器官移植杂志,1995,16(2):68-69. 被引量:10
  • 2卫生部,主编.艾滋病诊疗指南(草案)[M].2005.121-123.
  • 3Powierska CJ,Gospodarek E,Czerwionka SM.New aspects of epidemiology and treatment of Pneumocystis carinii infection[J].Pol Merkuriusz Lek,2004,9,17(101):534-537.
  • 4Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, doubleblind, muhicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother, 2002, 46:451 -457.
  • 5Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Micmhinl lnf~c.t Di~ 9f~i 99./170--/17/1.
  • 6Garbino J, Lew D, Hirschel B, et al. Caspofungin in the treatment of oropharyngeal candidiasis. Int J Clin Pract, 2003, 57 : 143 - 144.
  • 7Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol, 1994, 48:471 -497.
  • 8Denning DW. Eehinocandin antifungal drugs. Lancet, 2003, 362:1142 - 1151.
  • 9Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos, 2000, 28 : 1274 - 1278.
  • 10Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp. , including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother, 2003, 47:1068- 1071.

共引文献48

同被引文献123

引证文献8

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部